Skip to main content
Corterve
10 Studies Recruiting

Clinical Trials Near New Orleans, LA

Find research studies actively recruiting participants near New Orleans. Studies are run at established research institutions including Tulane Medical Center and Ochsner Health.

Top Research Institutions in New Orleans

1

Tulane Medical Center

2

Ochsner Health

3

LSU Health

Recruiting Studies Near New Orleans

#1

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

RECRUITINGPHASE2University of Oklahoma

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.

๐Ÿ“ Orlando, Florida๐Ÿ“ New Orleans, Louisiana๐Ÿ“ Albuquerque, New Mexico
#2

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

RECRUITINGPHASE3NRG Oncology

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

๐Ÿ“ Anchorage, Alaska๐Ÿ“ Anchorage, Alaska๐Ÿ“ Anchorage, Alaska
#3

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

RECRUITINGPHASE3SWOG Cancer Research Network

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

๐Ÿ“ La Jolla, California๐Ÿ“ Tampa, Florida๐Ÿ“ Chicago, Illinois
#4

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

RECRUITINGPHASE2Children's Oncology Group

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).

๐Ÿ“ Birmingham, Alabama๐Ÿ“ Mobile, Alabama๐Ÿ“ Anchorage, Alaska
#5

Vitamin D for Prostate Endocrine Therapy

RECRUITINGPHASE3University of Rochester

This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.

๐Ÿ“ Newark, Delaware๐Ÿ“ Newark, Delaware๐Ÿ“ Danville, Illinois
#6

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

RECRUITINGPHASE1, PHASE2Sanofi

This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older. The aim of the study is to evaluate the immunogenicity and safety of an RSV+HMPV vaccine candidate for the prevention of RSV and HMPV disease among adults 60 years of age and older. While there are 3 FDA approved/licensed RSV vaccines currently available to the public, no vaccine is available for the prevention of HMPV in older adults. This study is intended to provide data in support of further clinical development of the RSV+HMPV vaccine candidate. The study will consist of 4 cohorts and 11 vaccine groups (RSV+HMPV \[6 dose levels\], placebo and 4 control groups). The duration of the study will be approximately 12 months for each participant.

๐Ÿ“ Gadsden, Alabama๐Ÿ“ Vestavia Hills, Alabama๐Ÿ“ Huntington Beach, California
#7

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

RECRUITINGPHASE2National Cancer Institute (NCI)

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.

๐Ÿ“ Birmingham, Alabama๐Ÿ“ Little Rock, Arkansas๐Ÿ“ Downey, California
#8

Study of DONQ52 in Active Celiac Disease

RECRUITINGPHASE2Chugai Pharmaceutical

The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

๐Ÿ“ Anniston, Alabama๐Ÿ“ Homewood, Alabama๐Ÿ“ Mobile, Alabama
#9

Multicenter HomeVENT: Home Values and Experiences Navigation Track

RECRUITINGNAJohns Hopkins University

This is a multicenter study to test a decision-making support process for families and clinicians facing decisions about chronic home ventilation for a child. The investigators hypothesize that the intervention will increase family preparedness for decision-making and will improve clinician-family shared-decision making. Half of families will be assigned to "usual care" arm and half to the "intervention" arm. Intervention families will view the study website with study staff and will answer questions related to website content. All families will be interviewed and surveyed at 1, 6 and 12 months after enrollment. Each family will designate 1-2 physician involved in the decision about home ventilation; each physician will be interviewed and surveyed at 1 month.

๐Ÿ“ Tampa, Florida๐Ÿ“ New Orleans, Louisiana๐Ÿ“ Baltimore, Maryland
#10

Project: Every Child for Younger Patients With Cancer

RECRUITINGNot SpecifiedChildren's Oncology Group

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

๐Ÿ“ Birmingham, Alabama๐Ÿ“ Mobile, Alabama๐Ÿ“ Anchorage, Alaska

Clinical Trials in New Orleans: FAQ

How do I find clinical trials near New Orleans?

Corterve aggregates all actively recruiting clinical trials near New Orleans, LA from the ClinicalTrials.gov database. Simply browse the listings on this page or take our assessment to find trials that may be relevant.

Does it cost anything to take part in a study?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

What research institutions are located in New Orleans?

New Orleans is home to several leading research institutions, including Tulane Medical Center, Ochsner Health, LSU Health. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to see studies near you?

Take our assessment to see research studies recruiting near New Orleans that may be relevant. Study teams decide who joins.

See studies near you